Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. in Journal of gastrointestinal cancer / J Gastrointest Cancer. 2022 Jun;53(2):289-298. doi: 10.1007/s12029-021-00596-z. Epub 2021 Feb 5.

2022
ASL Biella
AO Ordine Mauriziano
AOU Città della Salute di Torino

Tipo pubblicazione

Multicenter Study

Autori/Collaboratori (30)Vedi tutti...

Casadei-Gardini A
Medical Oncology Department, Campus Biomedico University, Roma, Italy.
Cascinu S
Medical Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy.
Jeong JH
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

et alii...

Abstract

BACKGROUND AND AIM: The aim of the present study is to evaluate a new index (PECS (PsECogSii)index) influenced by PS ECOG and systemic immune-inflammation index (SII) in unresectable locally advanced or metastatic BTC patients treated with first-line chemotherapy. METHODS: This multicenter, international, study was conducted on a training cohort of 130 patients and in three European and Korean validation cohorts The PECS index was calculated as ECOG × SII index (neutrophil count × platelet count/lymphocyte count). Event-time distributions were estimated using the Kaplan-Meier method and survival curves were compared using the log-rank test. RESULTS: In the training cohort, the median overall survival (mOS) was 13.2 months, 8.7 months, and 3.8 months for patients with PECS-0, PECS-1, and PECS-2, respectively (PECS-0: HR = 1; PECS-1: HR 1.41; PECS-2: HR 3.23) (p < 0.0001). In the first validation cohort, the mOS was 12.8 months, 10.1 months, and 5.3 months for patients with PECS-0, PECS-1, and PECS-2, respectively (PECS-0: HR = 1; PECS-1: HR 1.29; PECS-2: HR 2.40) (p < 0.0001). In the second validation cohort, the mOS was 21.2 months, 10.2 months, and 3.0 months for patients with PECS-0, PECS-1, and PECS-2, respectively (PECS-0: HR = 1; PECS-1: HR 2.25; PECS-2: HR 9.00) (p < 0.0001). In the third validation cohort, the median OS was 15.5 months, 7.5 months, and 3.7 months for patients with PECS-0, PECS-1, and PECS-2, respectively (PECS-0: ref HR = 1; PECS-1: HR 2.14; PECS-2: HR 5.00) (p < 0.0001). Multivariate analysis in all cohorts confirmed the PECS index as an independent prognostic factor for OS. CONCLUSIONS: The easy assessment, low cost, and reproducibility make PECS index a promising tool to assess the prognosis of BTC patients in future clinical practice.

Accesso banca dati bibliografica

PMID : 33544375

DOI : 10.1007/s12029-021-00596-z

Keywords

Prognostic index; Prognosis; Gallbladder cancer; Cholangiocarcinoma; Chemotherapy; Biliary tract cancer; Retrospective Studies; Republic of Korea/epidemiology; Reproducibility of Results; Prognosis; Neutrophils/pathology; Lymphocytes/pathology; Biliary Tract Neoplasms/diagnosis/drug therapy/pathology; Humans; Inflammation; Survival;